Berlin, Germany – 22 July 2013 – caprotec bioanalytics GmbH and Bayer CropScience announced today that they have entered a second research collaboration to identify and elucidate a tractable agrochemical target using caprotec’s proprietary Capture Compound Mass Spectrometry technology (CCMS).
“We have decided to progress a second target with the team at caprotec and benefit from the close working relationships established over the last two years,” commented Dr. Markus Dollinger, Head of Pest Control Research at Bayer CropScience.
Building on the achievements of their initial collaborative project announced in December 2011, scientists at caprotec and Bayer CropScience will work together employing caprotec’s unique CCMS technology platform to support the elucidation of another novel target. As part of the collaboration, caprotec will profile the interactions of Bayer CropScience compounds with the proteome in relevant biological systems. Financial terms were not disclosed.
“We are pleased that Bayer CropScience has been able to experience the utility of our validated CCMS technology in the field of agrochemicals and we are very much looking forward to the continuation of our fruitful collaboration,” said Dr Jonathan Turner, CEO of caprotec. “Our CCMS enabling technology has unique potential in supporting challenging compound discovery and development programmes in the wider life science industry.”
Notes to Editors
About caprotec bioanalytics GmbH
caprotec bioanalytics GmbH is a Berlin-based biotech company focusing on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called capture compounds (CCs). They enable a targeted isolation and identification of proteins directly from complex biological samples in solution. The technology can be used in any species or tissue, to access proteins in any compartment, from cell surface to nucleus. As the leading, most widely applicable, platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in the identification, optimization and development to market of bioactive small molecules and the development of protein biomarkers. The technology is protected by a broad patent portfolio. The company is supported by an international scientific advisory board including one Nobel Laureate.
Issued for and on behalf of caprotec bioanalytics.
To contact the caprotec bioanalytics team at College Hill, email firstname.lastname@example.org